Home » Newsletters » BioWorld Science

BioWorld Science

May 15, 2014

View Archived Issues

Merck Research Laboratories describes discovery of potent HCV NS5B polymerase inhibitor prodrug

Domestic pesticide shows efficacy and safety for the treatment of INS

Early clinical and preclinical data presented for DS-5565

Shionogi presents highlights of fiscal 2013

Allecra Therapeutics reports on new potent beta-lactamase inhibitor

Chinese investigators test novel CLK1 inhibitors as anti-influenza agents

NOX4, a novel biomarker for non-valvular atrial fibrillation

Catabasis Pharmaceuticals presents preclinical data for CAT-2003

Aquilus Pharmaceuticals patents new MMP-13 inhibitors

Almirall divulges novel PI3Kdelta inhibitors

Calibr receives Gates Foundation research funding

Merck & Co. divulges new agents for HCV infection

Servier and Novartis enter into agreement for new drugs targeting apoptosis in oncology

Icahn School of Medicine awarded grant to investigate new therapy for eczema

Revive Therapeutics reports preclinical data for REV-003

BMS and Celldex Therapeutics to evaluate the combination of nivolumab and varlilumab

Daewoong Pharmaceutical synthesizes novel Na(V)1.7 blockers

Ono Pharmaceutical recaps progress of fourth quarter of fiscal 2013

Questcor licenses melanocortin peptides

Alexion studies ALXN-1007 for non-criteria manifestations of antiphospholipid syndrome

FDA grants nivolumab breakthrough therapy designation for Hodgkin's lymphoma

Novartis plans phase I/II study of CGF-166

Helix BioPharma seeks Canadian clearance for study of L-DOS47

ValiSeek reports encouraging results for VAL-401 development

Eisai resubmits additional benefit dossier for Fycompa in Germany

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 8, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.